These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 31071311)
1. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Polyzos SA; Perakakis N; Mantzoros CS Metabolism; 2019 Jul; 96():66-82. PubMed ID: 31071311 [TBL] [Abstract][Full Text] [Related]
2. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619 [TBL] [Abstract][Full Text] [Related]
3. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261 [TBL] [Abstract][Full Text] [Related]
4. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already? Machado MV; Cortez-Pinto H Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):513-5. PubMed ID: 23985000 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function. Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ F1000Res; 2019; 8():. PubMed ID: 31656583 [TBL] [Abstract][Full Text] [Related]
12. Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases. Vatier C; Vantyghem MC; Storey C; Jéru I; Christin-Maitre S; Fève B; Lascols O; Beltrand J; Carel JC; Vigouroux C; Bismuth E Curr Med Res Opin; 2019 Mar; 35(3):543-552. PubMed ID: 30296183 [TBL] [Abstract][Full Text] [Related]
13. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250 [TBL] [Abstract][Full Text] [Related]
14. Serum adiponectin and leptin levels in patients with lipodystrophies. Haque WA; Shimomura I; Matsuzawa Y; Garg A J Clin Endocrinol Metab; 2002 May; 87(5):2395. PubMed ID: 11994394 [TBL] [Abstract][Full Text] [Related]
15. Rationale for leptin-replacement therapy for severe lipodystrophy. Oral EA; Chan JL Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299 [TBL] [Abstract][Full Text] [Related]
16. Lipodystrophies. Garg A Am J Med; 2000 Feb; 108(2):143-52. PubMed ID: 11126308 [TBL] [Abstract][Full Text] [Related]
17. Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis. Casey SP; Lokan J; Testro A; Farquharson S; Connelly A; Proietto J; Angus PW Am J Transplant; 2013 Nov; 13(11):3031-4. PubMed ID: 24007548 [TBL] [Abstract][Full Text] [Related]
18. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy. Akinci G; Akinci B Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498 [TBL] [Abstract][Full Text] [Related]
19. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency. Antuna-Puente B; Boutet E; Vigouroux C; Lascols O; Slama L; Caron-Debarle M; Khallouf E; Lévy-Marchal C; Capeau J; Bastard JP; Magré J J Clin Endocrinol Metab; 2010 Mar; 95(3):1463-8. PubMed ID: 20097706 [TBL] [Abstract][Full Text] [Related]
20. Fatty Liver and Autoimmune Hepatitis: Two Forms of Liver Involvement in Lipodystrophies. Ribeiro A; Brandão JR; Cleto E; Santos M; Borges T; Santos Silva E GE Port J Gastroenterol; 2019 Aug; 26(5):362-369. PubMed ID: 31559327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]